

EP0048246.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>3</sup>: A61F 1/00; A61L 17/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 81/02667 (43) International Publication Date: 1 October 1981 (01.10.81)</p>
<p>(21) International Application Number: PCT/GB81/00058 (22) International Filing Date: 26 March 1981 (26.03.81) (31) Priority Application Numbers: 8010362 8011429 8032768 (32) Priority Dates: 27 March 1980 (27.03.80) 3 April 1980 (03.04.80) 10 October 1980 (10.10.80) (33) Priority Country: GB (71) Applicant (for all designated States except US): NATIONAL RESEARCH DEVELOPMENT CORPORATION [GB/GB]; P.O. Box 236, Kingsgate House, 66-74 Victoria Street, London SW1E 6SL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SCALES, John, Tracey [GB/GB]; 17 Brockley Avenue, Stanmore, Middlesex (GB). WILKINSON, Michael, John [GB/GB]; 46 Gills Hill Lane, Radlett, Hertfordshire (GB).</p>		<p>(74) Agents: BURFORD, Anthony, Frederick et al.; W H Beck, Greener &amp; Co, 7 Stone Buildings, Lincoln's Inn, London, WC2A 3SZ (GB). (81) Designated States: CH (European patent), DE (European patent), FR (European patent), GB (European patent), JP, US.  Published With international search report</p>
<p>(54) Title: ANTIMICROBIAL SURGICAL IMPLANTS</p> <p>(57) Abstract</p> <p>Surgical implants, especially endoprosthetic orthopaedic implants and sutures, are rendered antimicrobial by the presence of a bioerodible metallic silver component, especially a surface coating, which provides <i>in vivo</i> a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but insufficient to cause significant damage to connective tissue. Latently bioerodible silver components of an implant can be activated by, for example, abrasion, heating to above about 180°C or, especially, contact with hydrogen peroxide.</p> <div data-bbox="682 1197 1429 1806"> </div> <p style="text-align: center;"><b>BEST AVAILABLE COPY</b></p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	KP	Democratic People's Republic of Korea
AU	Australia	LI	Liechtenstein
BR	Brazil	LU	Luxembourg
CF	Central African Republic	MC	Monaco
CG	Congo	MG	Madagascar
CH	Switzerland	MW	Malawi
CM	Cameroon	NL	Netherlands
DE	Germany, Federal Republic of	NO	Norway
DK	Denmark	RO	Romania
FI	Finland	SE	Sweden
FR	France	SN	Senegal
GA	Gabon	SU	Soviet Union
GB	United Kingdom	TD	Chad
HU	Hungary	TG	Togo
JP	Japan	US	United States of America

- 1 -

ANTIMICROBIAL SURGICAL IMPLANTS

The present invention relates to surgical implants for the human or animal body and provides a manner of rendering such implants antimicrobial. The invention has particular, but not exclusive, application to  
05 endoprosthetic implants, especially orthopaedic implants.

As used in this Specification (including the Claims thereof), the term "surgical implant" means any inanimate article (including a device) which is to be  
10 surgically implanted in the human or animal body for a prolonged period. In particular, said term includes, for example, orthopaedic pins, plates and screws, tracheotomy tubes, artificial joints, artificial pacemakers, catheters, sutures and clips. References  
15 to "endoprosthetic implants" include the entire implant, parts thereof and fixing means therefor. Thus, in this Specification (including the Claims thereof, fixing pins and screws for use with endoprosthetic devices are included within the term "endoprosthetic  
20 implant".

With few exceptions, it has been the established practice for many years to manufacture surgical implants from materials which induce minimal tissue response and effects and yet possess adequate mechanical  
25 properties for the particular application. In the



- 2 -

particular case of endoprosthetic orthopaedic implants, structural materials have been sought which do not corrode in vivo and which do not cause bone reabsorption.

05        Materials used for orthopaedic implants have progressed from the early use of common metals and their alloys, especially mild steel, through the use of surgical stainless steel to the present day use of cobalt chromium molybdenum alloys and titanium  
10 and titanium alloys. Other materials which are used in endoprosthetic

- 3 -

orthopaedic implants include ceramic and carbon-based materials and some synthetic plastics materials such as ultra-high molecular weight polyethylene, some forms of nylon, polymethylmethacrylate and silicone elastomers.

05 None of these materials have fulfilled entirely the aim of bioinertness (i.e. bioinactivity) in all circumstances, but in general the attempt has been towards the use of more fully inert materials to prevent as far as possible any interaction in vivo. The search for materials

10 of greater bioinertness for use in surgical implants continues without diminution.

In the early years of implant surgery, silver was employed in the manufacture of endoprosthetic implants. In particular, silver wire, silver plates and silver-

15 plated screws were used in bone repair surgery and tracheotomy tubes were silver plated. However, the use of silver and silver plated implants had generally ceased by about 1935 in the ever continuing search for greater bioinertness for implant materials. In the particular

20 case of orthopaedic implants, silver was, and still is, considered to be unacceptable as an implant material, because of poor mechanical properties, connective tissue reaction and excessive subperiosteal bone growth (see, for example, Venable et al, Ann. Surg. 105, 917-938, 1937).

25 Silver was one of the first metals known to man. Silver artifacts have been found in tombs dating to

- 4 -

4,000 B.C. It is believed that in antiquity, silver was deliberately chosen for water receptacles to conserve the quality of drinking water. Silver needles have traditionally been used in acupuncture, which is one of the oldest forms of invasive medical treatment. The antimicrobial properties of silver compounds have been recognized for about 100 years. The first report of silver compounds for pharmaceutical use is that of aqueous silver nitrate for preventing eye infection in new born babies. Since then a range of silver salts, colloids and complexes have been employed to prevent and control infection. Colloidal metallic silver has been used topically for conjunctivitis, urethritis and vaginitis.

The antimicrobial activity of metallic silver has been exploited in filter elements for domestic and industrial use (see Disinfection, Sterilization, and Preservation; Editor S.S. Block, Publishers Lea and Febiger, Philadelphia, 1977). For this purpose, silver has been deposited on porous carbon or used in the form of a wire, gauze or other physical shape. It is believed that the active agent is the silver ion and that impurities must be present in the metal to expedite oxidation and solution.

The bodys ability to counter infection in the immediate vicinity of an implant is reduced thereby increasing the risk of a



- 5 -

localised infection around the implant. This risk persists beyond the immediate postoperative period and is a significant complication in implant surgery. It is usually difficult to treat such infection. Often  
05 additional surgery and sometimes removal of the implant is required in order to effectively treat the infection.

It has been proposed that inorganic silver compounds should be incorporated in bone cement to reduce the risk of postoperative infection following the insertion of  
10 an endoprosthetic orthopaedic implant. In particular, J.A. Spadaro et al (Clinical Orthopaedics and Related Research, 143, 266-270, 1979) proposed that low concentrations of inorganic silver compounds should be incorporated in polymethylmethacrylate bone cement for  
15 this purpose. The compounds which they evaluated for this purpose were silver chloride ( $\text{AgCl}$ ), silver oxide ( $\text{Ag}_2\text{O}$ ), silver sulphate ( $\text{Ag}_2\text{SO}_4$ ), silver phosphate ( $\text{Ag}_3\text{PO}_4$ ) and chlorided silver ( $\text{Ag-AgCl}$ ). They report that their proposal was based upon the known antibacterial  
20 effects of silver ions. The least effective of the compounds evaluated was chlorided silver which at 0.5% concentration did not inhibit any of the three bacteria tested, viz Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. In contrast, each of the other  
25 compounds evaluated significantly inhibited the bacteria at 0.5% concentration except for silver chloride which

- 6 -

did not inhibit Escherichia coli at that concentration.

It has also been reported by the same workers that electrically generated silver ions constitute a potent broad spectrum antibacterial agent of use as adjunctive treatment in the management of chronic osteomyelitis (Becker et al, J. Bone and Joint Surg., 60A, 871-881, 1978). The silver iontophoresis was used after standard surgical treatment for osteomyelitis, including debridement and the opening of all pockets of infection. When the wound was to be surgically closed, silver wire electrodes were temporarily inserted for a period of about six weeks. Electrical current was applied to the electrode from an external power source.

It is specifically stated in Becker et al (supra) that the clinical utility of silver is limited and, in particular, that diffusion of silver ions from a metallic surface such as silver foil is negligible. This statement is consistent with the absence, to the best of our knowledge, of any reported observation of significant antimicrobial activity when using the prior art silver or silver coated implants. Further, it is consistent with our own tests which have shown that commercially available 99.99% pure silver bar and foil do not inhibit the in vitro growth of Staphylococcus aureus.

Having regard to the above, the present state of the art can be summarized as being that, despite the reported



- 7 -

antimicrobial activity of certain forms of metallic silver and its use before about 1935 in surgical implants, the use of metallic silver in surgical implants is contraindicated.' Further, recent developments in the field of orthopaedic surgery teach the use of silver salts and electrically generated silver ions but not metallic silver surfaces for the prophylactic or adjunctive treatment of postoperative infections following implant surgery.

It is the object of the present invention to provide a simple, effective and surgically acceptable manner of rendering surgical implants antimicrobial to provide a prophylactic treatment of postoperative infection. Surprisingly, it has been found that this object can be achieved by going against the long-established teachings of the art and using metallic (including alloyed) silver, provided that two criteria are met. One criteria is that the metallic silver should be activated in the sense that it erodes in vivo to provide a sustained release of silver ions at a concentration sufficient to produce a localized antimicrobial effect but insufficient to cause significant damage to connective tissue. The other criteria is that the structural material of the implant should be a substantially bioinert material so that the mechanical integrity of the implant is retained despite



- 8 -

the erosion of the metallic silver.

According to one aspect of the present invention, there is provided a surgical implant having a composite form comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant and a bioerodible metallic silver component providing in vivo a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but insufficient to cause significant damage to connective tissue.

In another aspect of the present invention, there is provided a method of rendering antimicrobial a surgical implant comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant, said method comprising depositing on or in said implant a quantity of bioerodible metallic silver which will provide in vivo a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but insufficient to cause significant damage to connective tissue.

In a further aspect of the present invention, there is provided a method of rendering antimicrobial a surgical implant having a composite form comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant and a



- 9 -

latently bioerodible metallic silver component, said method comprising treating said implant to render said silver component bioerodible to provide in vivo a sustained release of silver ions in a concentration  
05 sufficient to provide a localized antimicrobial effect but insufficient to cause significant damage to connective tissue.

In yet another aspect of the present invention, there is provided a method of prophylactic treatment  
10 of postoperative infection following implant surgery, said method comprising selecting a surgical implant having a composite form comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant and a latently  
15 bioerodible metallic silver component, treating said selected insert to render the metallic silver component thereof bioerodible to provide in vivo a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but  
20 insufficient to cause significant damage to connective tissue, and surgically implanting the thus activated implant in the human or animal body.

As mentioned previously, the invention has particular, but not exclusive, application to endo-  
25 prosthetic implants, especially orthopaedic implants. However, the invention is applicable to any implant



- 10 -

which has permanent structural integrity. The  
implant can be made of any structural material which  
is substantially bioinert but usually will be made of  
titanium or titanium alloy, or cobalt chrome molyb-  
05 denum alloy, or ceramic material, or non-toxic  
synthetic plastics material, or any combination of  
these materials. Examples of implants to which the  
invention has particular application include ortho-  
paedic plates, pins and screws, artificial joints and  
10 sutures.

The metallic silver component can be made of  
commercially pure (i.e. 99.99%) silver metal or of  
a silver alloy, for example a dental amalgam or silver  
solder. In order to promote galvanic action produc-  
15 ing silver ions, there can be used an alloy of silver  
with a more noble metal such as gold or platinum.

Usually, but not necessarily, the silver compon-  
ent will be deposited in or on the permanent implant  
structure. Conveniently, the silver component is  
20 constituted by a surface coating on at least part of  
the implant structure. However, the component can  
be constituted in other ways, for example as a  
deposit in one or more cavities provided in the  
permanent implant structure or as a permeant in a  
25 porous substrate in or on the permanent implant  
structure.

- 11 -

The location of the silver component in the implant will be selected having regard to the structure and intended application of the implant. In the case of a silver coating, said coating can  
05 extend over all or only a selected part or parts of the implant structure. Similarly, in the case of cavity-deposited silver or permeant silver, the silver can be distributed over the implant structure or provided only at a selected part or parts thereof.

10 The quantity of silver in the composite implant and the rate of erosion in vivo is such as to provide a sustained release of silver ions in sufficient concentration to produce a localized antimicrobial effect but insufficient to produce significant damage  
15 to connective tissue. The required concentration balance readily can be achieved because antimicrobial activity is provided at a concentration of the order of nanogrammes/ml whereas connective tissue damage appears to require concentrations of six orders  
20 higher, i.e. milligrammes/ml. Nevertheless, the cumulative effects of sustained release of silver ions in the body must be considered when determining the quantity of silver to be used and the rate of erosion to avoid toxic effects in the human or animal body.  
25 Any osteogenesis produced by the antimicrobial concentrations of silver can be tolerated and in many



- 12 -

cases actually can be advantageous in that, for example, an orthopaedic implant is more securely located and/or the bone thickened in an area of weakness where it is joined to the implant.

05        It has been found that the quantity of silver in the composite implant suitably is the amount corresponding to a surface coating of 10 to 1000 Angstroms applied over the entire surface of the implant. This corresponds in the case of a large  
10        implant such as an artificial hip joint to not more than about 2 mg silver with proportionally smaller amounts of silver for smaller implants. Usually, an amount corresponding to such a coating of 25 to 500 Angstroms thick will be used.

15        It is an essential feature of the invention that the metallic silver component should be bioerodible to provide in vivo the silver ions required for the desired antimicrobial activity. As previously stated, metallic silver surfaces such as silver bar, silver  
20        foil and silver coatings applied by conventional plating techniques are not significantly antimicrobial or at least lose any antimicrobial activity shortly after manufacture. Moreover, the preoperative treatment of surgical implants at the time when silver or  
25        silver-plated implants were in use was such that the silver content of said implants would not have been

- 13 -

suitably activated to become antimicrobial. In particular, sterilization would have been conducted using temperatures of no more than about 100°C and/or sterilizing agents, such as alcohol, which do not activate the silver content to bioerode. However, there are a number of ways in which metallic silver can be rendered suitably bioerodible, including chemical, mechanical and/or thermal treatment as discussed below. It is expected that treatments additional to those discussed below will be apparent to those skilled in the metallurgical art.

An existing metallic silver surface can be activated by abrasion to freshly expose the metal surface. For example, the surface can be scratched with one or more pointed tools or, more usually, rubbed with an abrasive material or tool. In a particular embodiment of the invention in which the implant is an artificial joint, the silver component can comprise a coating on or deposit at a wear surface of the joint so that movement of the joint continually abrades the silver coating or deposit. In another embodiment, the silver is deposited in or on a substrate of a more readily bioerodible material, for

- 14 -

example iron, so that silver is released as the substrate erodes.

An existing metallic silver surface also can be activated thermally by heating to a temperature in excess of about 180°C. The duration of heating required to activate the surface will depend upon the temperature and the nature of the surface. Usually a temperature in the range 200° to 270°C will be used for a period of 16 to 60 mins. It has been found surprisingly that the surface is activated either in a molecular oxygen-containing atmosphere such as gaseous oxygen or air, or in an inert atmosphere, such as gaseous argon or nitrogen.

The presently preferred manner of activating existing metallic silver surfaces is to treat the surface with hydrogen peroxide. Preferably, the implant is immersed in the hydrogen peroxide. Suitably, 10 to 100 vols hydrogen peroxide is employed for a contact time of about 20 mins. The preference for this method is based upon convenience of use especially in view of the ready availability of hydrogen peroxide in operating theatres, where it is used to irrigate wounds at the time of operation.

The silver component can be deposited in an activated form by use of modern techniques such as sputter coating, film evaporation and ion implantation.





- 15 -

These techniques are well known per se in the metallurgical art and hence will not be discussed in detail. Selection of a particular technique can be made from the general knowledge of the properties of the deposit produced and/or by simple experiment to assess in vitro the antimicrobial activity of the deposit. It has been found, for example, that silk or terylene sutures can be satisfactorily coated with an active silver coating using sputter techniques.

The present invention affords many advantages over current proposals and methods of dealing with postoperative infection following implant surgery. In particular, it provides a prophylactic treatment which at least reduces the risk of postoperative infection and which can be regularly employed in implant surgery. The composite implant is self-contained requiring no energy source, such as electrical current, to produce the antimicrobial activity. Said activity is provided merely by bio-erosion of the silver component. The silver ions so released are not accompanied by irritant and toxic cations such as those generated by freely dissociable salts such as silver nitrate. Further, it is less likely that the \_\_\_\_\_

- 16 -

antimicrobial activity of silver ions will be circumvented by such relatively minor genetic mutation in a micro-organism as will often circumvent the antimicrobial activity of an antibiotic.

05       The following is a description, by way of example only and with reference to the accompanying drawings, of embodiments of the present invention. In the drawings:-

10       Figure 1 is a photograph of an incubated culture plate in which is located an implant pin which is partly coated with silver;

Figure 2 is a photograph of an incubated culture plate in which are located implant screws;

15       Figure 3 is a photograph of an incubated culture plate in which is located an implant screw completely coated with silver;

Figures 4, 5 and 6 are photographs of incubated culture plates in which are located implant screws which are partly coated with silver;

20       Figure 7 is a photograph of an incubated culture plate in which a silver bar was located during incubation but was subsequently removed;

Figure 8 is a photograph of an incubated culture plate in which is located a silver bar;

25       Figures 9, 10 and 11 are photographs of incubated culture plates in which are located silver foil discs.

- 17 -

Referring first to Figure 1, the bottom half 1  
of an implant pin 2 of titanium alloy type 318 was  
coated with silver by film evaporation. The thus  
coated pin was autoclaved in a conventional modern  
05 operating theatre autoclave with steam at about 140°C  
followed by a hot air drying cycle. After cooling,  
it was then placed on a culture plate 3 which had  
been inoculated with Staphylococcus aureus and the  
culture incubated for 24 hours. As can be seen in  
10 Figure 1, there was a clearly apparent zone 4 of  
inhibition around the silver coated bottom half 1 but  
no inhibition around the top half of the pin 2.

Referring now to Figure 2, three screws 5 of  
titanium alloy type 318 which had not been subjected  
15 to any special treatment were placed on a culture  
plate 23 which was inoculated and incubated as  
described above. As can be seen in Figure 2, there  
was no inhibition of Staph. aureus.

A titanium alloy screw identical to the screws  
20 5 of Figure 2 was completely coated with a 35 nm layer  
of silver by sputter coating and shortly thereafter  
the coated screw 35 (see Figure 3) was placed on a  
culture plate 33, which was inoculated and incubated  
as described above. As can be seen in Figure 3,  
25 there was a clearly apparent zone 34 of inhibition  
completely around the silver coated screw 35.



- 18 -

Three titanium alloy screws identical to the screws 5 of Figure 2 were coated with a 35 nm layer of silver at their upper halves only by sputter coating. The partly coated screws 45 (see Figure 4) were heated in air for 1 hour at 250°C and then autoclaved with steam at 120°C. After cooling, the autoclaved screws 45 were placed on a culture plate 43, which was inoculated and incubated as described above. As can be seen in Figure 4, there were clearly apparent zones 44 of inhibition around the coated upper halves of the screws 45 but no inhibition around their bottom halves.

Two titanium alloy screws identical to the screws 5 of Figure 2 were sputter coated with a 35 nm layer of silver at their upper halves only and subsequently heated in air for 1 hour at 250°C. After cooling, the partly coated screws 55 (see Figure 5) were placed on a culture plate 53, which was inoculated and incubated as described above. As can be seen in Figure 5, inhibition occurred only in zones 54 around the silver coated top halves of the screws 55.

Three titanium alloy screws identical to the screws 5 of Figure 2 were sputter coated with a 35 nm layer of silver at their upper halves only, subsequently heated in air for 1 hour at 250°C and then autoclaved in a theatre autoclave at 140°C with steam




- 19 -

followed by a hot air drying cycle. After cooling, the partly coated screws 65 (see Figure 6) were placed on a culture plate 63, which was inoculated and incubated as described above. As can be seen in Figure 6, inhibition occurred only in zones 64 around the silver coated top halves of the screws 65.

A commercially available silver bar (99.99% purity) was heated in air at 225°C for 1 hour and, after cooling, placed on an empty culture plate. Culture medium was poured onto the plate and then inoculated with Staph.aureus (top half) and E. coli (bottom half) and incubated as described above. As can be seen in Figure 7, there was a clearly apparent zone of inhibition surrounding the location of the silver bar (subsequently removed) in the culture plate 73.

The procedure described above with reference to Figure 7 was repeated except that the culture medium and bar 86 (see Figure 8) were refrigerated for 24 hours before inoculation. As can be seen in Figure 8, there was a clearly apparent zone 84 of inhibition in the culture plate 83 around the bar 86.

Four discs of silver foil (99.99% purity) 97 (see Figure 9) were heated at 270°C for 20 mins in gaseous oxygen and, after cooling, placed on a culture plate 93, which was inoculated and incubated as described above. As can be seen in Figure 9, there



- 20 -

were clearly apparent zones 94 of inhibition surrounding the discs 97.

The procedure described above with reference to Figure 9 was repeated except that the discs 107 (see 05 Figure 10) were heated in gaseous nitrogen instead of oxygen. As can be seen in Figure 10, there were clearly apparent zones 104 of inhibition in the culture plate 103 surrounding the discs 101.

Three discs of silver foil (99.99% purity) 117 10 (see Figure 11) were immersed in 100 vols hydrogen peroxide for 20 mins. The discs were thoroughly washed with water to remove all traces of hydrogen peroxide and then placed on a culture plate 113, which was inoculated and incubated as described above. As 15 can be seen in Figure 11, there were clearly apparent zones 114 of inhibition around the discs 113.

Similar results to those reported above have also been observed with Escherichia coli, with black silk and terylene sutures onto which silver has been 20 sputter coated, and with hydrogen peroxide activated silver alloy dental amalgam which is at least 15 years old. Further, tests with the activated foil discs 97, 107 and 117 show that their antimicrobial activity is retained for at least 8 weeks when stored in air at 25 room temperature.

- 21 -

CLAIMS

1. A surgical implant having a composite form comprising  
a substantially bioinert structural material providing  
permanent mechanical integrity to the implant and a  
bioerodible metallic silver component providing in vivo  
05 a sustained release of silver ions in a concentration  
sufficient to provide a localized antimicrobial effect  
but insufficient to cause significant damage to  
connective tissue.
2. A surgical implant as claimed in Claim 1 which is  
10 an endoprosthesis orthopaedic implant or a suture.
3. A surgical implant as claimed in Claim 1 wherein  
the metallic silver is a silver alloy.
4. A surgical implant as claimed in Claim 2 which is  
an artificial joint and the silver component is  
15 deposited at a wear surface.
5. A surgical implant as claimed in Claim 1 wherein the  
silver component is constituted by a surface coating  
on at least part of the implant structure.
6. A surgical implant as claimed in Claim 1 wherein the  
20 silver is deposited in or on a substrate of more  
readily bioerodible material.
7. A surgical implant as claimed in Claim 1 wherein the  
amount of silver in the composite implant would be  
sufficient to provide a surface coating of 25 to 500  
25 Angstroms thick applied over the entire surface of the  
implant.

- 22 -

8. A method of rendering antimicrobial a surgical implant having a composite form comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant and a latently bioerodible metallic silver component, said method comprising treating said implant to render said silver component bioerodible to provide in vivo a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but insufficient to cause significant damage to connective tissue.

9. A method as claimed in Claim 8 wherein said treatment to activate the latently bioerodible metallic silver component comprises heating at a temperature in excess of about 180°C.

10. A method as claimed in Claim 8 wherein said treatment to activate the latently bioerodible metallic silver component comprises contact with hydrogen peroxide.

11. A method of rendering antimicrobial a surgical implant comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant, said method comprising depositing on or in said implant a quantity of bioerodible metallic silver which will provide in vivo a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but insufficient to cause significant damage to connective tissue.





- 23 -

12. A method as claimed in Claim 11 wherein the silver is deposited as a surface coating on at least part of the permanent implant structure.


13. A method as claimed in Claim 11 wherein the surgical  
05 implant is an artificial joint and the silver is deposited on or at a wear surface.

14. A method as claimed in Claim 11 wherein the silver is deposited in or on a substrate of more readily bioerodible material.

10 15. A method as claimed in Claim 11 wherein the amount of silver deposited would be sufficient to provide a surface coating of 25 to 500 Angstroms thick applied over the entire surface of the implant.

16. A method as claimed in Claim 11 wherein the silver  
15 is deposited by sputter coating, film evaporation or ion implantation.

17. A method of prophylactic treatment of postoperative infection following implant surgery, said method comprising selecting a surgical implant having a  
20 composite form comprising a substantially bioinert structural material providing permanent mechanical integrity to the implant and a latently bioerodible metallic silver component, treating said selected insert to render the metallic silver component thereof  
25 bioerodible to provide in vivo a sustained release of silver ions in a concentration sufficient to provide a localized antimicrobial effect but insufficient to



- 24 -

cause significant damage to connective tissue,  
and surgically implanting the thus activated implant  
in the human or animal body.

18. A method as claimed in Claim 17 wherein said treatment  
05 to activate the latently bioerodible metallic silver  
component comprises heating at a temperature in excess  
of about 180°C.
19. A method as claimed in Claim 17 wherein said treatment  
to activate the latently bioerodible metallic silver  
10 component comprises contact with hydrogen peroxide.



1 / 6





FIG. 1.



FIG. 2.



BEST AVAILABLE COPY

BUREAU  
OMPI  
WIPO

2 / 6



BEST AVAILABLE COPY



3/6

FIG. 5.







FIG. 6.



BEST AVAILABLE COPY

4/6



BEST AVAILABLE COPY

5/6




FIG. 9.




FIG. 10.

BEST AVAILABLE COPY



6/6




FIG. 11.

BEST AVAILABLE COPY



# INTERNATIONAL SEARCH REPORT

International Application No. **PC 81/00058**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>3</sup> According to International Patent Classification (IPC) or to both National Classification and IPC <div style="margin-top: 10px;">Int.Cl.<sup>3</sup>: A 61 F 1/00; A 61 L 17/00</div>											
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched <sup>4</sup></div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">Int.Cl.<sup>3</sup></td> <td style="padding: 5px;">A 61 F 1/00; A 61 L 17/00</td> </tr> </table> <div style="margin-top: 10px; font-size: small;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>5</sup></div>			Classification System	Classification Symbols	Int.Cl. <sup>3</sup>	A 61 F 1/00; A 61 L 17/00					
Classification System	Classification Symbols										
Int.Cl. <sup>3</sup>	A 61 F 1/00; A 61 L 17/00										
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; padding: 5px;">Category <sup>6</sup></th> <th style="width: 60%; padding: 5px;">Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup></th> <th style="width: 30%; padding: 5px;">Relevant to Claim No. <sup>15</sup></th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US, A, 3932627, published January 13, 1976, H.W. Margraf</td> <td></td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US, A, 3557795, published January 26, 1971, E. Weck &amp; Company</td> <td></td> </tr> </table>			Category <sup>6</sup>	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>15</sup>	A	US, A, 3932627, published January 13, 1976, H.W. Margraf		A	US, A, 3557795, published January 26, 1971, E. Weck & Company	
Category <sup>6</sup>	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>15</sup>									
A	US, A, 3932627, published January 13, 1976, H.W. Margraf										
A	US, A, 3557795, published January 26, 1971, E. Weck & Company										
<div style="font-size: x-small;"> <sup>*</sup> Special categories of cited documents: <sup>13</sup>  <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document cited for special reason other than those referred to in the other categories</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> </div> <div style="width: 45%;"> <p>"P" document published prior to the international filing date but on or after the priority date claimed</p> <p>"T" later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance</p> </div> </div> </div>											
<b>IV. CERTIFICATION</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">           Date of the Actual Completion of the International Search <sup>1</sup>  <div style="margin-top: 10px; font-size: large;">June 29, 1981</div> </td> <td style="width: 50%; padding: 5px;">           Date of Mailing of this International Search Report <sup>2</sup>  <div style="margin-top: 10px; font-size: large;">July 13, 1981</div> </td> </tr> <tr> <td style="padding: 5px;">           International Searching Authority <sup>1</sup>            EUROPEAN PATENT OFFICE Branch at The Hague            P.O.Box 5818 Patentlaan, 2            2280 HV RIJSWIJK (ZH) The Netherlands         </td> <td style="padding: 5px;">           Signature of Authorized Officer <sup>20</sup>  <div style="text-align: center; margin-top: 10px;"> <div style="display: flex; justify-content: center; align-items: center;"> <div style="width: 50px; height: 50px; border: 1px solid black; margin-right: 10px;"></div> <div style="text-align: left;">G.L.M. Kruidenberg</div> </div> </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <sup>1</sup> <div style="margin-top: 10px; font-size: large;">June 29, 1981</div>	Date of Mailing of this International Search Report <sup>2</sup> <div style="margin-top: 10px; font-size: large;">July 13, 1981</div>	International Searching Authority <sup>1</sup> EUROPEAN PATENT OFFICE Branch at The Hague P.O.Box 5818 Patentlaan, 2 2280 HV RIJSWIJK (ZH) The Netherlands	Signature of Authorized Officer <sup>20</sup> <div style="text-align: center; margin-top: 10px;"> <div style="display: flex; justify-content: center; align-items: center;"> <div style="width: 50px; height: 50px; border: 1px solid black; margin-right: 10px;"></div> <div style="text-align: left;">G.L.M. Kruidenberg</div> </div> </div>					
Date of the Actual Completion of the International Search <sup>1</sup> <div style="margin-top: 10px; font-size: large;">June 29, 1981</div>	Date of Mailing of this International Search Report <sup>2</sup> <div style="margin-top: 10px; font-size: large;">July 13, 1981</div>										
International Searching Authority <sup>1</sup> EUROPEAN PATENT OFFICE Branch at The Hague P.O.Box 5818 Patentlaan, 2 2280 HV RIJSWIJK (ZH) The Netherlands	Signature of Authorized Officer <sup>20</sup> <div style="text-align: center; margin-top: 10px;"> <div style="display: flex; justify-content: center; align-items: center;"> <div style="width: 50px; height: 50px; border: 1px solid black; margin-right: 10px;"></div> <div style="text-align: left;">G.L.M. Kruidenberg</div> </div> </div>										

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☒ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**